Company intelligence / Profile preview
Prelude Therapeutics
Wilmington, Delaware, USApreludetx.com ↗
- Ownership
- Public · PRLD
- Employees
- ~125
- Development stage
- Phase 1
01
Overview
Prelude’s lead program PRT3789, an IV SMARCA2 degrader, has shown encouraging early clinical activity and safety in Phase 1 trials for SMARCA4-deficient NSCLC and other cancers. Partial responses were observed with a generally well-tolerated profile. An oral version (PRT7732) entered Phase 1 enrollment. The company’s Precision ADC platform demonstrated promising preclinical tumor regression data. Their selective CDK9 inhibitor PRT2527 showed activity in relapsed/refractory lymphoid malignancies but will require a partner to advance further as focus shifts to the degrader portfolio.[5][7][8]
- Therapeutic areas
- OncologyHematology
- Modalities
- Small molecules (SMARCA2 degraders, CDK9 inhibitors)Antibody-drug conjugates (ADCs) via targeted protein degradation[1][3][5]
- Industry
- Biotech
02
Drug pipeline
18 assets17 more assets in the full pipeline.
03
Partnerships
AbCellera—collaboration on next-generation precision antibody-drug conjugates using targeted protein degradation technology.[10]
04
Financials
- Market cap
- $205.8M
- Total revenue
- $12.1M
- Enterprise value
- $71.7M
Beyond the preview
Go deeper on Prelude Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Prelude Therapeutics.